Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex

Pedro M Folegatti1, Amy Flaxman1, Daniel Jenkin1

  • 1The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.

Vaccines
|April 3, 2021
PubMed

Insights

A prime-boost vaccine strategy using Modified Vaccinia Ankara (MVA) and a simian adenovirus vector showed good safety and induced T-cell immune responses against Mycobacterium avium subspecies paratuberculosis.

Area of Science:

  • Vaccinology
  • Immunology
  • Infectious Diseases

Background:

  • Heterologous prime-boost vaccination strategies enhance immune responses in viral vectored vaccines.
  • Mycobacterium avium subspecies paratuberculosis (MAP) causes Johne's disease in ruminants, posing economic challenges to the livestock industry.

Purpose of the Study:

  • To evaluate the safety and immunogenicity of a Modified Vaccinia Ankara (MVA) vectored vaccine expressing four MAP antigens.
  • To assess the vaccine's efficacy as a single dose or as a booster following a simian adenovirus (ChAdOx2) prime.

Main Methods:

  • The study involved administering a poxvirus MVA vectored vaccine, either alone or after a ChAdOx2 prime.
  • Safety and T-cell immune responses were monitored in the vaccinated subjects.

Main Results:

  • The heterologous prime-boost schedule using ChAdOx2 followed by MVA was well tolerated.
  • This prime-boost approach successfully induced significant T-cell immune responses.

Conclusions:

  • A heterologous prime-boost vaccination strategy with ChAdOx2 and MVA is safe and effective in eliciting T-cell immunity.
  • This approach holds promise for developing vaccines against Mycobacterium avium subspecies paratuberculosis.